Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.

导出 OA

翻译打印收藏纠错

作者： Raj K,Maturi ^[1] ; Adam R,Glassman ^[2] ; Kristin,Josic ^[2] ; Carl W,Baker ^[3] ; Adam T,Gerstenblith ^[4] ; Lee M,Jampol ^[5] ; Annal,Meleth ^[6] ; Daniel F,Martin ^[7] ; Michele,Melia ^[2] ; Omar S,Punjabi ^[8] ; Soraya,Rofagha ^[9] ; Hani,Salehi-Had ^[10] ; Cynthia R,Stockdale ^[2] ; Jennifer K,Sun ^[11] ; DRCR Retina Network

作者单位： Midwest Eye Institute, Indianapolis, Indiana.;Department of Ophthalmology, Indiana University School of Medicine, Indianapolis. ^[1] Jaeb Center for Health Research, Tampa, Florida. ^[2] Hilton Head Retina Institute, Hilton Head Island, South Carolina. ^[3] Mid Atlantic Retina Specialists, Hagerstown, Maryland. ^[4] Feinberg School of Medicine, Northwestern University, Chicago, Illinois. ^[5] Marietta Eye Clinic, Douglasville, Georgia. ^[6] Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. ^[7] Charlotte Eye Ear Nose and Throat Associates PA, Charlotte, North Carolina. ^[8] East Bay Retina Consultants, Inc, Oakland, California. ^[9] Retina Associates of Southern California, Huntington Beach. ^[10] Joslin Diabetes Center, Beetham Eye Institute, Harvard Department of Ophthalmology, Boston, Massachusetts. ^[11]